Indian Gastroesophageal Reflux Disease Therapeutics market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Gastroesophageal reflux disease (GERD) is defined as a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications. The prevalence of GERD in India ranges from 7.6% to 30%, being < 10% in most population studies, and higher in cohort studies. The dietary factors associated with GERD include use of spices and non-vegetarian food. Helicobacter pylori is thought to have a negative relation with GERD; H. pylori negative patients have higher grade of symptoms of GERD and esophagitis. Less than 10% of GERD patients in India have erosive esophagitis. GERD is highly prevalent in southern India. Increasing age and BMI, an urban environment, lower educational level. Several factors such as increasing obesity, change in diet and lifestyle, smoking, and use of specific food types can affect the prevalence of GERD in this rapidly progressing society. The increasing prevalence of GERD, along with the growing risk factor population, is likely to increase the demand for proton pump inhibitors, which in turn, is expected to drive the market.
The consumption of alcohol will affect the prevalence of gastroesophageal reflux disease. The increasing consumption of alcohol will affect the overall prevalence of the disease and could contribute to the overall market growth. Proton pump inhibitors are gold standard medication for gastroesophageal reflux disease (GERD), and the increasing prevalence of GERD and the rising acceptance of novel drug delivery systems are the two most prominent factors driving the growth of the market. The risk factors such as aging, obesity, delayed stomach emptying, changing lifestyles associated with smoking, consumption of alcohol, coffee, fatty, and fried foods are the major reasons for the occurrence of GERD.